INSMED INC Payments of Stock Issuance Costs
INSMED INC (INSM) reported Payments of Stock Issuance Costs of $39.20 million for the 1-month period ending 2025-06-30, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-02-19
- INSMED INC payments of stock issuance costs for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- INSMED INC payments of stock issuance costs for the quarter ending 2024-03-31 was $409.00K.
- INSMED INC payments of stock issuance costs for the quarter ending 2023-03-31 was $0.00.
- INSMED INC payments of stock issuance costs for the quarter ending 2022-12-31 was $16.20M.
| Period end | Payments of Stock Issuance Costs | Payments of Stock Issuance Costs 0 month | Payments of Stock Issuance Costs 1 month | Payments of Stock Issuance Costs 1 month as first filed | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 3 month as first filed | Payments of Stock Issuance Costs 6 month |
|---|---|---|---|---|---|---|---|
| 2025-06-30 | $39.20M 10-K · filed 2026-02-19 | $39.40M 10-Q · filed 2025-08-07 | |||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | ||||||
| 2024-05-31 | $34.30M 10-K · filed 2026-02-19 | ||||||
| 2024-03-31 | $409.00K 10-Q · filed 2025-05-08 | ||||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $16.20M derived: sum of 2 quarters · filed 2025-02-20 | |||||
| 2022-12-31 | $16.20M 10-K · filed 2025-02-20 | ||||||
| 2022-10-31 | $16.20M 10-Q · filed 2024-10-31 | ||||||
| 2022-10-19 | $16.20M 10-K · filed 2023-02-23 | ||||||
| 2021-06-30 | $17.50M 10-K · filed 2024-02-22 | ||||||
| 2020-06-30 | $13.50M 10-K · filed 2023-02-23 | $13.40M 10-Q · filed 2020-08-06 | |||||
| 2019-06-30 | $16.00M 10-K · filed 2022-02-17 | ||||||
| 2019-05-24 | $16.00M 10-K · filed 2021-02-25 | ||||||
| 2017-09-30 | $24.80M 10-K · filed 2020-02-25 | ||||||
| 2017-09-06 | $24.80M 10-Q · filed 2017-11-02 | ||||||
| 2015-04-30 | $14.50M 10-K · filed 2018-02-23 | ||||||
| 2015-04-06 | $14.50M 10-Q · filed 2016-11-03 | ||||||
| 2014-08-31 | $7.10M 10-K · filed 2017-02-23 | ||||||
| 2014-08-18 | $7.10M 10-K · filed 2016-02-25 | ||||||
| 2013-07-22 | $4.70M 10-K · filed 2016-02-25 | $4.70M 10-Q · filed 2014-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |